Neu1 Antibody

What are the primary applications of NEU1 antibodies in research?

NEU1 antibodies are extensively used in multiple experimental techniques, with the most common applications being:

• Western Blotting (WB): Detecting NEU1 protein (45-48 kDa) in cell and tissue lysates

• Immunohistochemistry (IHC): Visualizing NEU1 distribution in tissue sections

• Immunofluorescence (IF): Determining subcellular localization

• Immunoprecipitation (IP): Isolating NEU1 protein complexes

• ELISA: Quantifying NEU1 protein levels

Different antibody clones may perform optimally in specific applications. For example, the F-8 clone (sc-166824) has demonstrated efficacy across multiple applications including WB, IP, IF, IHC, and ELISA .

What is the optimal protocol for immunodetection of NEU1 in tissue samples?

For optimal immunohistochemical detection of NEU1:

• Fixation: Formalin-fixed, paraffin-embedded sections are commonly used

• Antigen retrieval: Use TE buffer (pH 9.0) or alternatively citrate buffer (pH 6.0)

• Antibody dilution: 1:150-1:600 is recommended for most monoclonal antibodies

• Incubation conditions: Typically overnight at 4°C

• Detection system: HRP-conjugated secondary antibodies or fluorescent labels

• Controls: Include pancreatic tissue as positive control (NEU1 is highly expressed in pancreas)

For paraffin sections, some antibodies like clone F-8 have been validated for IHCP applications with consistent results across multiple tissue types .

What species reactivity should be considered when selecting NEU1 antibodies?

When selecting NEU1 antibodies, consider these species reactivity patterns:

Note that species cross-reactivity varies significantly between antibody clones. Always validate reactivity when working with animal models, especially for antibodies not explicitly tested in your species of interest .

How can NEU1 antibodies be used to investigate the dual localization of NEU1 in lysosomes and at the plasma membrane?

To investigate the dual localization of NEU1:

• Subcellular fractionation approach:

  • Isolate lysosomal and plasma membrane fractions using differential centrifugation

  • Confirm fraction purity using markers (LAMP1 for lysosomes, Na+/K+ ATPase for plasma membrane)

  • Detect NEU1 in each fraction by Western blotting (recommended dilution 1:1000-1:6000)

  • Quantify relative distribution between compartments

• Imaging approach:

  • Perform dual immunofluorescence with NEU1 antibody (1:50-1:500 dilution) and compartment markers

  • For plasma membrane NEU1: Use non-permeabilized cells or surface biotinylation

  • For lysosomal NEU1: Co-stain with LAMP1 or LysoTracker

  • Apply high-resolution microscopy (confocal or STED) to distinguish membrane vs. internal staining

Research has shown that NEU1 complexes with PPCA and β-galactosidase in lysosomes, but also exists at the cell surface where it regulates receptor sialylation and signaling processes .

What methodological approaches can be used to study NEU1's role in desialylation of cell surface receptors?

To investigate NEU1's desialylation activity on cell surface receptors:

• Receptor sialylation analysis:

  • Immunoprecipitate the receptor of interest (e.g., PDGF or IGF-1 receptors)

  • Detect sialylation using lectins (SNA or MAL-II) that recognize sialic acids

  • Compare sialylation in conditions with NEU1 inhibition/knockdown/overexpression

• NEU1 enzyme activity manipulation:

  • Use siRNA-mediated knockdown of NEU1 (validated approaches show ~80% reduction in NEU1 expression)

  • Apply pharmacological inhibition with neuraminidase inhibitors

  • Alternatively, use NEU1-specific antibodies that block catalytic activity

  • Verify enzyme activity using fluorogenic substrates (e.g., 4-MU-NANA)

• Functional consequences:

  • Assess downstream signaling of the target receptor through phosphorylation studies

  • Evaluate cellular responses like proliferation, migration, or adhesion

Research has demonstrated that NEU1 desialylation of PDGF and IGF receptors reduces their activation and downstream signaling, suggesting NEU1 plays a role in limiting cellular proliferation .

How can immunoprecipitation with NEU1 antibodies be optimized to study the NEU1-PPCA-β-galactosidase complex?

For optimal co-immunoprecipitation of the NEU1-PPCA-β-galactosidase complex:

• Lysis conditions:

  • Use mild detergents (0.5-1% NP-40 or Triton X-100) to preserve protein-protein interactions

  • Include protease inhibitors to prevent degradation

  • Maintain pH around 5.5-6.0 to preserve lysosomal protein interactions

• Immunoprecipitation strategy:

  • Pre-clear lysate with protein G beads to reduce non-specific binding

  • Incubate with NEU1 antibody (3-5 μg per mg of total protein) at 4°C for 4-6 hours

  • For NEU1 pull-down, monoclonal antibodies like clone F-8 at 3 μg/ml have shown efficacy

  • Wash stringently but maintain complex integrity

• Detection of complex components:

  • Western blot for NEU1 (45 kDa), PPCA (protective protein cathepsin A), and β-galactosidase

  • Verify complex formation by reverse IP using anti-PPCA antibodies

  • Assess neuraminidase activity in the immunoprecipitated complex using fluorogenic substrates

Studies have shown that NEU1 forms a heterotrimeric complex with PPCA and β-galactosidase, which is essential for its stability and enzymatic activity. PPCA pull-down co-immunoprecipitates active NEU1, confirming their physical association .

What are the considerations for using NEU1 antibodies to study NEU1 release from activated immune cells?

When investigating NEU1 release from activated immune cells:

• Experimental design:

  • Stimulate cells with appropriate activators (e.g., LPS at 100 ng/ml for microglia/macrophages)

  • Collect conditioned media at optimal timepoints (18-24 hours post-stimulation)

  • Concentrate supernatants (10-100× using 10 kDa cutoff filters) for detection

• Detection methods:

  • Western blot analysis of concentrated supernatants (look for 45 kDa band)

  • Measure neuraminidase activity in supernatants using fluorogenic substrates

  • Validate specificity via NEU1 knockdown studies

• Controls and validation:

  • Use NEU1 siRNA to confirm specificity (validated protocols show ~80% knockdown)

  • Include vacuolin-1 to inhibit lysosomal exocytosis

  • Measure other lysosomal enzymes (e.g., cathepsin activity) as secretion controls

Research has demonstrated that activated microglia release NEU1 through lysosomal exocytosis, and this extracellular NEU1 can modulate microglial phagocytosis and neuroinflammatory responses .

How can NEU1 antibodies be used to investigate the relationship between NEU1 deficiency and disease pathology?

For studying NEU1 deficiency in disease contexts:

• Tissue microarray (TMA) analysis:

  • Use validated NEU1 antibodies (1:150-1:600 dilution) on patient tissue sections

  • Quantify expression levels using digital pathology algorithms

  • Compare with markers of lysosomal dysfunction (e.g., LAMP1)

  • Correlate with clinical parameters and disease severity

• Cell-based models:

  • Generate NEU1-deficient cell lines using CRISPR/Cas9 or siRNA

  • Reconstitute with wild-type or mutant NEU1 constructs

  • Assess phenotypic changes related to lysosomal function, receptor signaling, and cellular behavior

• Analysis of sialylated substrates:

  • Examine sialylation status of known NEU1 substrates

  • Look for accumulation of hypersialylated glycoproteins in patient samples

  • Assess downstream functional consequences

Research has shown that NEU1 deficiency correlates with increased cell surface LAMP1 expression in rhabdomyosarcoma, suggesting enhanced exocytic activity. Low NEU1 expression has also been associated with altered receptor signaling in multiple disease contexts .

What strategies can be employed to distinguish between the catalytic activity and protein-protein interaction functions of NEU1 using antibodies?

To differentiate between NEU1's catalytic and scaffolding functions:

• Domain-specific antibodies:

  • Use antibodies targeting different epitopes of NEU1:

    • N-terminal antibodies (may affect protein interactions)

    • C-terminal antibodies (may affect catalytic site access)

    • Antibodies targeting the catalytic domain (amino acids 210-415)

• Functional blocking studies:

  • Apply antibodies to intact cells to block surface-exposed domains

  • Compare effects on:

    • Neuraminidase activity (using fluorogenic substrates)

    • Protein complex formation (via co-immunoprecipitation)

    • Downstream signaling pathways

• Correlation with catalytic mutants:

  • Use catalytically inactive NEU1 mutants as comparison

  • Assess which antibody effects mimic the catalytic mutant phenotype

  • Identify effects that persist despite catalytic inactivity

Research indicates that NEU1 antibodies can block enzymatic activity when applied to intact cells, affecting processes like receptor desialylation, while some NEU1 functions may be independent of its catalytic activity and related to its role in protein complexes .

What are common issues with detecting NEU1 in Western blotting and how can they be resolved?

Common Western blotting issues with NEU1 antibodies:

• Multiple bands or unexpected molecular weight:

  • Expected size: 45-48 kDa for full-length NEU1

  • Higher bands (60-70 kDa): May represent glycosylated forms

  • Lower bands: Potential degradation products or alternative splice variants

  Solution: Use fresh samples with protease inhibitors, optimize sample preparation conditions, and verify with positive control tissues (pancreas, liver).

• Weak or no signal:

  • NEU1 is moderately expressed in most tissues

  • Highest in pancreas, followed by skeletal muscle, kidney, placenta, heart, lung, and liver

  Solution: Optimize antibody concentration (1:500-1:1000 for initial tests), extend exposure time, use enhanced chemiluminescent substrate, and enrich samples through immunoprecipitation if necessary.

• Non-specific background:

  • Common with polyclonal antibodies against NEU1

  Solution: Increase blocking time (5% milk or BSA for 2 hours), optimize antibody dilution, use monoclonal antibodies like clone F-8 or 67032-1-Ig that show high specificity in Western blotting applications .

How should experiments be designed to account for potential differences between native and recombinant NEU1 detection?

When comparing native and recombinant NEU1:

• Expression system considerations:

  • Human NEU1 contains three N-glycosylation sites (N186, N343, N352)

  • Insect cell-derived recombinant NEU1 (e.g., Sf21 cells) has different glycosylation patterns

  • Mammalian expression systems more closely reflect native glycosylation

  Controls: Include both recombinant standards and native positive controls in experiments

• Antibody selection:

  • Choose antibodies validated for both native and recombinant proteins

  • Some antibodies preferentially recognize specific glycoforms

  • For recombinant proteins, antibodies raised against amino acids 210-415 show good recognition

  Approach: Test multiple antibody clones when transitioning between native and recombinant systems

• Activity considerations:

  • Recombinant NEU1 often has lower activity without PPCA co-expression

  • Native NEU1 functions in complex with PPCA and β-galactosidase

  Solution: Co-express PPCA when working with recombinant NEU1 for functional studies

Research has shown that recombinant NEU1 can form in cellulo crystals when overexpressed, which may affect antibody accessibility and activity measurements compared to native NEU1 .

What controls and validation steps are essential when establishing NEU1 knockdown or knockout studies?

Essential controls for NEU1 knockdown/knockout studies:

• Expression validation:

  • Western blot: Confirm protein reduction using validated antibodies (1:1000-1:6000 dilution)

  • qPCR: Verify mRNA reduction (validated primers: fwd 5′-TTCATCGCCATGAGGAGGTCCA and rev 5′-AAAGGGAATGCCGCTCACTCCA)

  • Immunofluorescence: Visualize cellular NEU1 distribution changes

• Functional validation:

  • Neuraminidase activity assay: Measure using fluorogenic substrates at appropriate pH (optimal at pH 4.5 for lysosomal activity, pH 7.2 for cell surface activity)

  • Substrate accumulation: Look for increased sialylated glycoproteins

  • Rescue experiments: Reintroduce wild-type NEU1 to confirm phenotype specificity

• Control considerations:

  • Non-targeting siRNA/sgRNA controls

  • Partial knockdown controls to detect dose-dependent effects

  • Multiple knockdown/knockout clones to control for off-target effects

Research demonstrates that efficient NEU1 knockdown (>80% reduction) can be achieved using siRNA approaches in multiple cell types. Knockdown validation by both gene expression and functional assays is critical, as residual activity may be sufficient for some NEU1 functions .

How can NEU1 antibodies be used to investigate the role of NEU1 in regulating elastin deposition and tissue elasticity?

Investigating NEU1's role in elastin regulation:

• Tissue analysis approach:

  • Dual immunostaining for NEU1 (1:150-1:600) and elastin/microfibrillar proteins

  • Analysis of co-localization in elastic fiber-rich tissues

  • Quantification of elastin deposition relative to NEU1 expression levels

• Functional studies:

  • Use blocking NEU1 antibodies to inhibit surface activity

  • Assess elastin binding protein (EBP) complex formation

  • Measure desialylation of microfibrillar glycoproteins

  • Quantify insoluble elastin formation under different NEU1 conditions

• Cell culture models:

  • Analyze elastin-producing cells (smooth muscle cells, fibroblasts)

  • Manipulate NEU1 expression/activity and evaluate effects on:

    • Tropoelastin secretion

    • Crosslinking and fiber assembly

    • Growth factor sequestration in elastic matrices

Research has established that cell surface-residing NEU1 desialylates microfibrillar glycoproteins, facilitating proper elastic fiber assembly. NEU1 antibodies can be used to block this activity, demonstrating NEU1's crucial role in elastin deposition and tissue elasticity .

What methodological approaches can elucidate the involvement of NEU1 in regulating microglial activation and neuroinflammation?

To investigate NEU1's role in microglial activation:

• NEU1 activity modulation in microglia:

  • siRNA knockdown: Validated approaches show ~80% reduction in microglial NEU1

  • Pharmacological inhibition: NEU1-selective inhibitors like C9-butyl-amide-DANA

  • Antibody blockade: Apply anti-NEU1 antibodies to intact cells

• Functional assessment:

  • Phagocytosis assays: Measure bead uptake or neuronal debris clearance

  • Migration assays: Analyze microglial motility in wound healing assays

  • Inflammatory response: Quantify cytokine production and signaling pathway activation

  • Neuronal toxicity: Co-culture systems with microglia and neurons

• Mechanistic analysis:

  • Assess sialylation status of microglial receptors

  • Examine lysosomal exocytosis using LAMP1 surface expression

  • Investigate neuraminidase activity in microglial supernatants

Studies have demonstrated that microglia release NEU1 upon LPS stimulation through lysosomal exocytosis. This extracellular NEU1 can regulate microglial phagocytosis and potentially contribute to neuroinflammatory processes and neuronal toxicity .

How can researchers utilize NEU1 antibodies to investigate the interplay between NEU1 and signaling pathways in cancer progression?

For studying NEU1 in cancer signaling:

• Expression and localization analysis:

  • Compare NEU1 expression in tumor vs. normal tissues using IHC (1:150-1:600)

  • Assess subcellular distribution using fractionation and immunofluorescence

  • Correlate with cancer progression markers and patient outcomes

• Signaling pathway interactions:

  • Immunoprecipitate NEU1 and blot for associated signaling molecules

  • Assess receptor sialylation status (PDGF, IGF-1, etc.) in NEU1-manipulated cells

  • Monitor downstream signaling activation through phosphorylation studies

  • Analyze feedback regulation between NEU1 and oncogenic pathways

• Functional consequences:

  • Investigate cell migration, invasion, and proliferation in response to NEU1 modulation

  • Examine exosome release and composition (using LAMP1 as marker)

  • Assess tumor microenvironment interactions

Research has shown that low NEU1 expression correlates with increased LAMP1 surface expression in rhabdomyosarcoma, suggesting enhanced exocytic activity. Additionally, NEU1 can desialylate growth factor receptors like PDGF and IGF-1 receptors, potentially regulating cancer cell proliferation and migration .